Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Osteitis Deformans × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 318 Neoplasm Metastasis 27 Stomach Neoplasms 25 Breast Neoplasms, Male 23 Neoplasms 15 Inflammatory Breast Neoplasms 11 Brain Neoplasms 10 Esophageal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Urinary Bladder Neoplasms 5 Prostatic Neoplasms 5 Pancreatic Neoplasms 5 Sarcoma 4 Rectal Neoplasms 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Adenocarcinoma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Triple Negative Breast Neoplasms 3 Salivary Gland Neoplasms 3 Lung Neoplasms 3 HER2-positive Breast Cancer 3 Cardiotoxicity 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Adenocarcinoma Of Esophagus 3 Vulvar Neoplasms 2 Vipoma 2 Vaginal Neoplasms 2 Uterine Cervical Neoplasms 2

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡